UNSPSC 51162703: Amidephrine

This classification denotes a decongestant and an alpha-adrenergic agonist with the molecular formula C10H16N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E2P22546V, chemically known as 3-(1-hydroxy-2-(methylamino)ethyl)methanesulfonanilide, but more generally known as amidephrine, which bears US NIH Compound Identifier 15010. As of Q4 2014, AMIDEPHRINE remains US FDA's Preferred Term for this commodity. Amidephrine bears US NLM identifiers UMLS ID C0051584 and NCI Concept Code C79522. SMILES: CNCC(C1=CC(=CC=C1)NS(=O)(=O)C)O.

UNSPSC 51162703 Amidephrine is a Commodity code that covers pharmaceutical compounds used in parenteral and injectable medical products supplied to state and local healthcare and correctional facilities. State and local governments procure amidephrine primarily as a component in intravenous solutions, parenteral nutrition formulations, and other injectable pharmaceutical preparations delivered to correctional health systems, public health departments, and emergency medical services. The issuing bodies are correctional departments, county health agencies, and specialized public health authorities responsible for providing medically necessary pharmaceuticals to incarcerated populations and community health programs.

Recent activity centers on Washington state and Florida. The Washington State Department of Corrections posted RFQ RFQQK13020 on September 8, 2026, seeking parenteral products, services, and equipment for eight correctional facilities across three regions (West, Central, and East), with responses due October 7, 2026 at 4:00 PM PST; DOC anticipates awarding up to three contractors per region and requires delivery of parenteral nutrition bags within 24 hours of order and other parenteral products within 8 hours. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for naloxone and drug deactivation systems with quarterly deliveries to the county community health building, though the solicitation due date of July 26, 2023, appears to be a historical reference. The Washington procurement emphasizes compliance with Chapter 39.19 RCW regarding minority and women-owned business utilization with aspirational 5% Small and Diverse Business Goals, and requires documented experience preparing and delivering IV solutions with ability to adjust parenteral nutrition preparations. Both jurisdictions require commercial general liability, professional liability, and business automobile liability coverage; the Washington opportunity also mandates cyber liability insurance.